Fisiopatología y tratamiento de la hemorragia crítica: una revisión de la literatura

Celia González-Guerrero, José Bruno Montoro-Ronsano

Resumen


Objetivos: desarrollar los factores implicados en la fisiopatología de la coagulopatía asociada al traumatismo (CAT) mediante una revisión de la literatura publicada al respecto; además de revisar la evidencia disponible sobre el tratamiento de la hemorragia crítica y las recomendaciones de las guías de práctica clínica. Métodos: se ha realizado una búsqueda de la bibliografía publicada sobre la fisiopatología y tratamiento de la hemorragia crítica en las bases de datos PUBMED, BestPractice, UpToDate y la Biblioteca Cochrane Plus. Las principales palabras clave utilizadas para la búsqueda han sido: “early trauma induced coagulopathy”, “mechanisms of early trauma-induced coagulopathy”, “blood transfusión guidelines”, “massive transfusion guidelines” y ”fibrinogen replacement therapy”. Los artículos más clínicamente relevantes han sido seleccionados para la revisión. Conclusiones: la fisiopatología de la coagulopatía asociada al traumatismo se trata de un cuadro más complejo y multifactorial de lo que inicialmente se había aceptado. El tratamiento precoz de la coagulopatía es imprescindible para el manejo inicial de la hemorragia crítica. No obstante, el uso de hemoderivados debería ser racional y basado en una evidencia científica homogénea y de alta calidad. Los principales pilares del tratamiento de la hemorragia crítica son la fluidoterapia, el concentrado de fibrinógeno, el concentrado de complejo protrombínico, el plasma, los concentrados de hematíes o de plaquetas, el ácido tranexámico y el calcio. Su administración debería valorarse en función de las condiciones clínicas de cada paciente.

Palabras clave


Tratamiento de la hemorragia crítica; Fisiopatología de la coagulopatía asociada al traumatismo; Fibrinógeno; Complejo de protrombina; Hemoderivados

Texto completo:

PDF (English)

Referencias


Cardenas JC., Wade CE., et Holcomb JB. Mechanisms of trauma-induced coagulopathy. Curr Opin Hematol 2014, 21:404-409.

Brohi K., Singh J., Heron M. et Coats C. Acute traumatic coagulopathy. J Trauma 2003, 54:1127-1130.

MackLeod JBA, Lynn M, Mckenney MG, Cohn SM et Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma 2003, 55:39-44.

Oshiro et al. Critical Care 2014, 18:R61 http://ccforum.com/content/18/2/R61

Stephanie A. Smith. The cell-based model of coagulation. Vet Emerg Crit Care 2009;19(1):3-10.

Hoffman M., Monroe DM. A cell-based model of Hemostasis. Thromb Haemost 2001;85:958-65.

Ross Davenport. Coagulopathy following major trauma hemorrhage: lytic, lethal and a lack of fibrinogen. Critical Care 2014, 18:151 http://ccforum.com/content/18/3/151

Brown LM, Call MS, Margaret Knudson M, et al. A normal platelet count may not be enough: the impact of admission platelet count on mortality and transfusion in severely injured trauma patients. J Trauma 2011; 71 (Suppl 3):S337-S342.

Wohlauer MV, Moore EE, Thomas S, et al. Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma. J Am Coll Surg 2012;214:739-746.

Kutcher ME, Redick BJ, McCreery RC, et al. Characterization of platelet dysfunction after trauma. J Trauma Acute Care Surg 2012;73:13-19.

Sillesen M., Rasmussen LS, Jin G. et al. Assessment of coagulopathy, endotelial injury, and inflammation after traumatic brain injury and hemorrhage in a porcine model. J Trauma Acute Care Surg 2014;76:12-19.

Ostrowski SR., Johansson PI. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy. J Trauma Acute Care Surg 2012; 73:60-66.

Cohen MJ, Call M, Nelson M, et al. Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. Ann Surg 2012;255:379-385.

Chesebro BB, Rahn P., Carles M., et al. Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock 2009;32:659-665.

Closa D., Folch-Puy E. Oxygen free radicals and the systematic inflammatory response. IUBMB Life 2004;56:185-191.

Wood MJ., Helena Prieto J., Komives EA. Structural and functional consequences of methionine oxidation in thrombomodulin. Biochim Biophys Acta 2005;1703:141-147.

Burney PR, White N, Pfaendtner J. Structural effects of methionine oxidation on isolated dubdomains of human fibrin D and alphaC regions. PloS One 2014;9:e86981.

Raza I., Davenport R., Rourke C., et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost 2013;11:307-314.

Lustenberger T., Relja B., Puttkammer B., et al. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) levels are decreased in patients with trauma-induced coagulopathy. Thromb Res 2013;131:e26-30.

Levy JH et al. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. TRANSFUSION 2014; 54:1389-1405.

Schlimp CJ., Schöhl H. The role of fibrinogen in trauma-induced coagulopathy. Hämostaseologie 2014; 34.

Massimo Franchini, Giuseppe Lippi. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus 2012; 10: 23-7

Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3: 1894-904.

Rahe-Meyer N, Sørensen B. Fibrinogen concentrate for management of bleeding. J Thromb Haemost 2011; 9: 1-5.

Aubron C, Reade M.C et al. Efficacy and safety of fibrinogen concentrate in trauma patients- a systematic review. Journal of Critical Care 2014; 29:471.e11-471.e17

Leal-Noval SR, Muñoz M, Asuero M, et al. Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document". Blood Transfus 2013; 11: 585-610.

Association of Anaesthetists of Great Britain and Ireland, Thomas D, Wee M, Clyburn P, et al. Blood transfusion and the anaesthetist: management of massive haemorrhage. Anaesthesia 2010;65:1153-61

UK Blood Transfusion & Tissue Transplantation Services. The handbook for transfusion medicine. 2007. [cited 2014 August 6]. Available from: http://www.transfusionguidelines.org.uk/docs/pdfs/htm_edition-4_all-pages.pdf

American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report. Anesthesiology 2006; 105:198-208.

National Advisory Committee on Blood and Blood Products. Guidelines for massive transfusion. 2011. [cited 2014 August 6]. Available from: http://www.nacblood.ca/resources/guidelines/massive-transfusion.html

Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013;17:R76.

Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guideline s from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013;30:270-382.

Leal-Noval SR., López-Irizo R., et al. Efficacy of the prothrombin complex concentrate in patients requiring urgent reversal of vitamin K antagonists or presenting with uncontrolled bleeding: a retrospective, single center study. Blood Coagulation and Fibrinolysis 2013, 24: 862-868.

Mendarte L, Munne M et al. Use of Human Prothrombin Complex Concentrate in patients with Acquired Deficiency an Active or in High-Risk Severe Bleeding. Journal of Coagulation Disorders 2010

Huttner HB, Schellinger PD, et al. Hematoma growth and outcome in treated neurocritical care patients with intracraneal hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006;37:1465-70.

Siddiq F, Jalil A, et al. Effectiveness of factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage. Neurocrit Care 2008;8:36-41.

Stanworth SJ, Brunskill SJ, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004,126:139-152.

Kozek-Langenecker et al. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Critical Care 2011, 15:R239

Schimp et al. Impact of fibrinogen concentrate alone or with prothrombin complex concentrate (+/− fresh frozen plasma) on plasma fibrinogen level and fibrin-based clot strength (FIBTEM) in major trauma: a retrospective study. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2013, 21:74

Peyrou V, Lormeau JC, Herault JP, Gaich C, Pfliegger AM, Herbert JM. Contribution of erythrocytes to thrombin generation in whole blood Thromb Haemost 1999, 81:400-406.

CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T,

Dewan Y, et al. Effects of tranexamic acid on death, vascular occlusive events, and

blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a

randomised, placebo-controlled trial. Lancet 2010;376:23-32.

Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of

Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg

;147:113-9.

Yunos NM, Bellomo R, et al. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 2012; 308(15):1566-72

Perner, A. et al. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 2012; 367(2):124-134.

Brunkhorst, F.M. et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis . N Engl J Med 2008; 358(2):125-139.

Myburgh, J.A. et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367(20):1901-1911.

AEMPS, October 2013: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2013/NI-MUH_FV_29-hidroxietil-almidon.htm




DOI: http://dx.doi.org/10.7399%2Ffh.2015.39.6.8907

Enlaces refback

  • No hay ningún enlace refback.


Incluida en:

Bibliovigilance Dialnet DOAJ Dulcinea EBSCO Embase ESCI Ibecs Latindex MEDES mEDRA MIAR PUBMED REDALYC Redib SciELO SCOPUS Sherpa/Romero

Farmacia Hospitalaria

Sociedad Española de Farmacia Hospitalaria. C/ Serrano n. 40 2º Dcha. - 28001 Madrid

eISSN: 2171-8695 

ISSN-L: 1130-6343

Dep. Legal: M-39835-2012

Correo electrónico de contacto: [email protected]

Los artículos publicados en esta revista se distribuyen con la licencia: Creative Commons Attribution 4.0.

La revista Farmacia Hospitalaria no cobra tasas por el envío de trabajos, ni tampoco cuotas por la publicación de sus artículos.